Aardvark Therapeutics, Inc.
Clinical trials sponsored by Aardvark Therapeutics, Inc., explained in plain language.
-
New hope for rare hunger disorder: Long-Term drug trial underway
Disease control TerminatedThis study tests whether ARD-101 can safely reduce extreme hunger and food-related behaviors in people with Prader-Willi syndrome over 12 months. About 90 participants who completed a prior study will take the drug daily and visit the clinic regularly. The goal is to see if the d…
Phase: PHASE3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 06:44 UTC
-
Hope for rare hunger disorder: new drug trial targets Prader-Willi symptoms
Symptom relief TerminatedThis study tests whether the drug ARD-101 can reduce the intense, constant hunger (hyperphagia) seen in people with Prader-Willi syndrome. About 90 participants will take either ARD-101 or a placebo daily for 12 weeks. Researchers will track changes in hunger-related behaviors an…
Phase: PHASE3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Symptom relief
Last updated May 26, 2026 06:56 UTC